The international success of GLP-1 agonists for weight loss is overwhelming pharma safety operations as they strive to monitor incoming adverse events, says Daniel O’keeffe of Qinecsa Solutions.
Their soaring popularity as a weight-loss aid has overwhelmed the pharma industry, which is seeing unforeseen volumes of new safety work as the products’ success continues to go viral internationally.
